Adhesion of ZAP-70+ chronic lymphocytic leukemia cells to stromal cells is enhanced by cytokines and blocked by inhibitors of the PI3-kinase pathway  by Lafarge, Sandrine T. et al.
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CLL  cell  survival  and  proliferation  is  enhanced  through  direct  contact  with  supporting  cells  present  in
lymphoid  tissues.  PI3Ks  are  critical  signal  transduction  enzymes  controlling  B cell  survival  and  activation.
PI3K  inhibitors  have entered  clinical  trials  and  show  promising  therapeutic  activity;  however,  it  is  unclear
whether  PI3K  inhibitor  drugs  differentially  affect  ZAP-70  positive  versus  negative  CLL  cells  or  target  spe-
ciﬁc microenvironmental  interactions.  Here  we provide  evidence  that  CD40L  + IL-4,  IL-8 or IL-6  enhance
adhesion  to stromal  cells,  with  IL-6  showing  a  selective  effect  on ZAP-70  positive  cells.  Stimulatory  effects
of  IL-8  or  IL-6  are  fully  reversed  by  PI3K  inhibition,  while  the effects  of CD40L  + IL-4  are partially  reversed.AP-70
icroenvironment
L-6
L-8
D40L
L-4
While  CD40L  + IL-4  is the only  stimulation  increasing  CLL  cell  survival  for all patient  groups,  IL-6  protects
ZAP-70  positive  cells  from  cell  death  induced  by  PI3K  inhibition.  Altogether,  our  results  indicate  that
targeting  the PI3K  pathway  can  reverse  protective  CLL–microenvironment  interactions  in both  ZAP-70
positive  and  negative  CLL  despite  their  differences  in  cytokine  responsiveness.
© 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-SA license.
I3K pathway
. Introduction
Chronic lymphocytic leukemia (CLL) is the most prevalent form
f adult leukemia in Western countries and remains incurable. CLL
s characterized by the progressive accumulation of mature, mono-
lonal CD5+ CD19+ CD23+ B lymphocytes in the peripheral blood,
ymph nodes, spleen and bone marrow [1]. CLL cells can present
n absence of mutations in the immunoglobulin variable region
enes (IgVH) and can over-express zeta-chain TCR-associated pro-
ein kinase 70 kDa (ZAP-70) which both are correlated with the
ggressiveness of the disease [2]. Nowadays, they are deﬁned as
LL biomarkers.
Lymphoid tissue microenvironments play a major role in
LL by providing extrinsic survival signals for CLL cells. Spon-
aneous CLL cell apoptosis observed in vitro can be prevented
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E-mail address: marshall@ms.umanitoba.ca (A.J. Marshall).
145-2126     ©  2013 The Authors. Published by Elsevier Ltd. 
ttp://dx.doi.org/10.1016/j.leukres.2013.08.001
Open access under CC BY-NC-SA with T-cell-derived cytokines (such as CD40L and IL-4) [3,4] or
by co-culture with mesenchymal stromal cells derived from bone
marrow [5,6]. Stromal cells promote early B cell development
and mature B cell survival through direct cell contact and soluble
factors [7,8]. Additional microenviromental factors may inﬂuence
CLL, including inﬂammatory cytokines such as interleukin-6 (IL-6)
and interleukin-8 (IL-8), which are elevated in plasma from CLL
patients with worse clinical course [9–11].
The current treatments for CLL (Chlorambucil, Fludarabine, anti-
CD20 Rituximab, etc.) induce apoptosis in CLL cells but lead to
signiﬁcant immune-suppression and patients often develop drug
resistance [12]. There is currently no approved treatment for
CLL that speciﬁcally block signaling pathways promoting CLL cell
survival; however several kinase inhibitors are currently being
evaluated, including inhibitors of Syk, Btk and phosphoinositide
3-kinase (PI3K). Recent evidence has strongly implicated PI3Ks as
critical signaling enzymes impacting CLL survival and response
to microenvironmental stimuli [13,14]. Critical receptors on CLL
such as antigen receptor (BCR) and IL-4 receptor activate the PI3K
enzymes (p110 , , , ), which then phosphorylate membrane
phosphoinositides on the D3 position to generate second messen-
gers such as phosphatidylinositol 3,4,5-triphosphate (PIP3). PIP3
recruits and activates Akt and a number of other signaling proteins
involved in differentiation, growth, proliferation and survival of B
license.
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ells [15]. The PI3K signaling pathway is constitutively active in CLL
ells and inhibiting this pathway reduces CLL survival in vitro [16].
ecent work indicates that pan-PI3K inhibitors untie CLL cells from
tromal cells and induce CLL cell apoptosis [13]. CAL-101/GS-1101,
 PI3K p110 inhibitor promoted apoptosis in primary CLL cells ex
ivo and this toxicity was  not diminished by co-culture on stro-
al  cells [17,18]. Moreover, clinical trials using CAL-101 showed
romising preliminary results in the ability to release CLL cells from
ymph nodes into the blood, where cells are less protected and more
ensitive to treatments [18]. It is currently not clear whether CLL
ells from the ZAP-70 positive and negative prognostic groups dif-
er in their sensitivity to PI3K inhibitors or whether the response
o these new therapeutics are affected by inﬂammatory cytokines
resent in some patients.
In this study, we investigated whether or not CLL cells from
AP-70 positive and negative patients differ in their capacity to
dhere to stromal cells in response to cytokine stimulation and their
ensitivity to PI3K pathway inhibition. We  discovered that ZAP-
0 positive CLL cells show higher adhesion capacity in response
o some inﬂammatory cytokines. PI3K inhibitors are effective in
educing stromal cell adhesion of both ZAP-70 positive and neg-
tive CLL cells and can reverse the enhanced adhesion induced by
nﬂammatory cytokines. These results suggest that ZAP-70 positive
nd negative CLL interact differently with the stromal microenvi-
onment, and this can potentially be inﬂuenced by inﬂammatory
ytokines which may  impact their respective retention and survival
n lymphoid tissues. PI3K inhibition may  be an effective strategy for
locking stromal cell interaction with therapeutic beneﬁt for both
AP-70 positive and negative CLL patients.
. Methods
.1. CLL patients and prognostic markers
Peripheral blood from CLL patients was obtained from the Manitoba CLL Clinic
nd Tumor Bank following informed consent, with the approval of the Research
thics Board at the University of Manitoba. CLL cells were stained with anti-CD19-
450, anti-CD5-APC, anti-CD3-APC-Cy7, anti-CD38-PE (all from BD Biosciences) for
5  min  at room temperature (RT). After washing, cells were ﬁxed and permeabilized
sing IntraPrep Reagent 1&2 (Beckman Coulter) and further stained with anti-ZAP-
0-FITC (Beckman Coulter). 7-AAD (BD Biosciences) was  also added as a control of
he ﬁxation/permeabilization process. After washing, cells were analyzed by ﬂow
ytometry using a FACS Canto II or LSR-II instrument (BD Biosciences). The cutoff
or CD38 and ZAP-70 positivity was 7% and 25%, respectively as these cutoffs were
ecently shown to be more clinically relevant [19,20]. IgVH mutation status was
etermined by PCR ampliﬁcation and DNA sequencing as previously described [21].
.2. CLL cell isolation
Mononuclear cells were isolated using a Ficoll-Paque density gradient as pre-
iously described [21]. Contaminating cells were removed using B Cell Enrichment
osettes (StemCell Technologies) according to the manufacturer’s protocol. Resid-
al  red cells were removed using ACK lysis buffer (Sigma). CLL cells were cultured
n  complete RPMI-1640.
.3. CLL cell co-culture with stromal cells
S17 stromal cells were generously provided by Dr. Kenneth Dorshkind, UCLA
22]. 48-well plates were seeded with S17 cells at 5 × 104/well in complete Opti-
EM  and cultured over-night. Culture medium was  then aspirated from wells and
LL cells at 5 × 106mL–1 in complete RPMI-1640 were added. Recombinant human
D40L, IL-4, IL-6 or IL-8 (all from R&D Systems) were reconstituted in sterile PBS
olution and used at 50 ng/mL (ﬁnal concentration). PBS was used as a control. The
I3K inhibitor PI-103 [23] (Cayman Chemical Company), CAL-101 and GDC-0941
both from Selleck) were dissolved in DMSO (Sigma) and used at a ﬁnal concentration
f 1.43 M,  5 M and 5 M,  respectively. An equal ﬁnal concentration of DMSO was
dded to control wells..4. Co-culture adhesion assay
We used an assay adapted from Kurtova et al. [5]. After 24 h co-culture, CLL cells
ot  adhered to the stromal cells were harvested by pipetting three times. Stromal
ell-bound cells were trypsinized for 5 min  in the presence of 0.25% EDTA (Sigma).earch 38 (2014) 109– 115
Trypsinized cells were harvested and wells were washed once with complete RPMI-
1640. Both stromal cell-bound and unbound cell fractions were stained for 15 min at
RT with anti-CD19-V450, anti-CD5-APC, anti-CD3-APC-Cy7, 7-AAD and AnnexinV-
FITC (all from BD Biosciences). Of note, trypsinization did not affect the expression
of  cells markers (data not shown). The absolute numbers of live B cells in the stro-
mal  cell-bound or unbound fractions were determined by ﬂow cytometry analysis
on  a FACS Canto-II instrument (BD Biosciences) by acquiring for 30 s after gating on
CD19+CD5+CD3−7-AAD−AnnexinV−  cells. The percentage of adhesion was calcu-
lated by dividing the number of stromal cell-bound CLL cells by the number of total
cells (bound + unbound fractions).
2.5. Co-culture survival assay
After 24 h or 48 h co-culture, CLL cells were harvested and the per-
centage of live (7-AAD−AnnexinV−), apoptotic (7-AAD−AnnexinV+) and dead
(7-AAD+AnnexinV+) cells were determined by ﬂow cytometry.
3. Results
3.1. Inhibition of the PI3K pathway blocks binding of CLL cells to
stromal cells
CLL cells were co-cultured with stromal cells for 24 h result-
ing in binding of CLL cells. The bound and unbound fractions were
separated by repeated washing of the stromal layer and each cel-
lular fraction was  analyzed by ﬂow cytometry (Fig. 1A). The PI3K
signaling enzymes are proposed to play important roles in CLL cell
interaction with microenvironments and are thus being actively
pursued as new therapeutic targets [13,17,24]. We  examined the
impact of PI3K pathway inhibition on stromal cell binding, and
asked whether ZAP-70 positive and negative subgroups may  dif-
fer in their dependence on this pathway. We treated cells with
PI-103, a potent PI3K inhibitor and precursor to the drug GDC-
0941 that has recently entered clinical trials [23]. PI-103 treatment
was found to decrease stromal cell adhesion by 35% on average
(Fig. 1B), consistent with recent studies [13]. The PI3K inhibitors
GDC-0941 or CAL-101 reduced CLL cell binding to stromal cells to
a similar extent as PI-103 (Fig. 1B). Next, we  assessed the effect
of PI3K inhibitors on Akt activation and observed that all three
inhibitors decreased Akt phosphorylation (Figure S1). Of 56 CLL
patients examined (Table S1), 7 patients did not show any differ-
ence in CLL cell adhesion to stromal cells after PI-103 treatment.
Interestingly, most of these non-responders were either ZAP-70
negative patients, discordants (ZAP-70 negative and unmutated
IgVH or ZAP-70 positive and mutated IgVH) or previously treated
(Table S1). We  further compared the impact of PI3K inhibition
on adhesion capacity of ZAP-70 positive and negative patients.
When all samples were normalized to their own control (DMSO
treatment), we observed signiﬁcant decreases in both groups: 22%
decrease in the ZAP-70 negative group and 39% decrease in the ZAP-
70 positive group (Fig. 1C). These results suggest that PI3K pathway
inhibition can partially block CLL cell adhesion to stromal cells and
tends to be more effective in reversing the adhesion capability of
ZAP-70 positive CLL cells.
Supplementary data associated with this article can be found,
in the online version, at http://dx.doi.org/10.1016/j.leukres.2013.
08.001.
3.2. Inhibition of the PI3K pathway impairs survival of CLL cell in
stromal cell co-culture
Stromal cell binding and other microenvironmental interactions
are known to inﬂuence CLL cell survival [25,26]. We also exam-
ined the effect of PI3K inhibition on CLL cell survival in stromal
cell co-cultures using 7-AAD and AnnexinV (Fig. 2A). Inhibition of
the PI3K pathway using different inhibitors resulted in a signiﬁ-
cant decrease in CLL cell survival (Fig. 2B). After 24 h co-culture, we
observed a signiﬁcant decrease in survival with PI-103 treatment
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Fig. 1. PI3K inhibition impairs CLL adhesion to S17 stromal cells. (A) Representa-
tive dot plots showing scatter proﬁles and CD19/CD3 staining of non-adherent and
adherent CLL cells harvested from stromal cell co-cultures. The relative numbers of
live  B cells in the bound and unbound fractions were determined by ﬂow cytometry
by  acquiring for exactly 30 s after gating on live CD19+ CD3− cells. (B and C) Pan-
PI3K inhibitor PI-103 (500 ng/mL), PI3K-selective inhibitor CAL-101 (5 M),  PI3K
inhibitor GDC-0941 (5 M)  or vehicle control DMSO were added to CLL-stromal cell
co-cultures and percent adhesion was determined. (B) Normalized percentage of
CLL cells bound to S17 stromal cells with different PI3K inhibitor treatment. To nor-
malize, the reference used for each sample was  the percent adhesion with DMSO
control treatment. Results shown represent median normalized numbers from 13
different patients. Error bars represent the interquartile range. Statistical signiﬁ-
cance (*p < 0.05) between treatments was analyzed by Friedman test with Dunn’s
multiple comparison post test. (C) Normalized percentages of ZAP-70 positive and
negative CLL adhesion to stromal cells. The data is from 56 different patients. Statis-
tical signiﬁcance between DMSO and PI-103 treatments was  analyzed by Wilcoxon
paired test. Statistics reported were calculated with absolute percentages.
Fig. 2. PI3K inhibition induces CLL apoptosis. CLL cells were co-cultured with stro-
mal  cells in the presence or absence of PI3K inhibitors. After one or two  day
co-culture, CLL cells were harvested and percentage of live (7-AAD− and AnnexinV−
cells), apoptotic (7-AAD− and AnnexinV+ cells) and dead (7-AAD+ and AnnexinV+
cells) cells were determined by ﬂow cytometry. (A) Representative dot plots show-
ing  AnnexinV/7-AAD staining proﬁles with or without PI-103. (B) Percentage of live
CLL cells with DMSO, PI-103 (500 ng/mL), CAL-101 (5 M)  or GDC-0941 (5 M)  treat-
ment. Results are shown in box plot as median numbers of live cells, ﬁrst and third
quartiles, maximum and minimum values from 13 different patients. Statistical sig-
niﬁcance (*p < 0.05) between DMSO and PI3 K inhibitor treatments was analyzed
by  Friedman test with Dunn’s multiple comparison post test. (C and D) Percentage
of  live CLL cells with DMSO or PI-103 (500 ng/mL) treatment after one (C) or two
(D) day co-culture in ZAP-70 positive and negative patient groups. The data is from
56  different patients. Statistical signiﬁcance (†p < 0.05) between DMSO and PI-103
treatments was  analyzed by Wilcoxon paired test.
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Fig. 3. Inﬂuence of T cell derived or inﬂammatory cytokines and ZAP-70 status on
PI3K inhibitor-induced CLL apoptosis. PBS, IL-6, IL-8 or CD40L + IL-4 (all at 50 ng/mL)
were added to CLL-stromal cell co-cultures, with or without PI-103. After one (A)
or  two  (B) day co-culture, the percentage of live (7-AAD− and AnnexinV− cells),
apoptotic (7-AAD− and AnnexinV+ cells) and dead (7-AAD+ and AnnexinV+ cells)
cells were determined by ﬂow cytometry. Results are shown in box plot as median
numbers of live cells, ﬁrst and third quartiles, maximum and minimum values from
23  different patients. Statistical signiﬁcance (†p < 0.05) between DMSO and PI-103
treatments was analyzed by Wilcoxon paired test. Since these statistics reﬂect sig-
niﬁcant differences for all conditions, they are not shown in the ﬁgure. Statistical12 S.T. Lafarge et al. / Leukem
n both ZAP-70 positive and negative patient groups (Fig. 2C). Sim-
lar results were seen after 48 h co-culture (Fig. 2D). However, 5
atients showed no change in cell survival in response to PI-103
reatment. Interestingly, 4 of these patients were ZAP-70 positive
nd have an unmutated IgH using VH1 (U VH1 – Table S1). These
ata demonstrate that PI3K inhibition effectively impairs CLL cell
urvival in the presence of stromal cells for the majority of ZAP-70
ositive and negative CLL patients.
.3. Impact of PI3K inhibition on CLL survival in the context of
tromal cells, CD40L and cytokines
We  further examined the signiﬁcance of PI3K signaling in CLL
urvival and adhesion in the context of pro-inﬂammatory stim-
li present in CLL patients. T cell-derived factors CD40L and IL-4
re thought to be present in tissue-associated proliferation cen-
ers and support CLL survival [3,4]. Although their role in CLL is
ot well deﬁned, IL-6 and IL-8 are elevated in plasma from CLL
atients with worse clinical course [9–11] and are associated with
oor prognosis in elderly CLL patients [27]. We  performed CLL-
tromal cell co-cultures in the presence of IL-6, IL-8 or CD40L + IL-4
nd determined their impact on CLL survival in co-culture. After
4 h or 48 h co-culture, the only stimuli giving rise to a signif-
cant increase of CLL cell survival was CD40L + IL-4 stimulation
or both ZAP-70 positive and negative groups (Fig. 3A and B).
I3K inhibition by PI-103 results in a signiﬁcant decrease of CLL
ell adhesion in all conditions (Fig. 3 – signiﬁcance †  not shown).
nly CD40L + IL-4 stimulation signiﬁcantly protected both ZAP-
0 positive and negative CLL cells from PI-103 induced death
Fig. 3). IL-8 did not have a signiﬁcant effect on CLL cell survival
n co-culture and did not protect from PI-103 induced cell death
hereas IL-6 did partially protect cells from PI-103 in the ZAP-
0 positive group only (Fig. 3B). These results suggest that PI3K
nhibition can signiﬁcantly impact survival of both ZAP-70 positive
nd negative CLL in the presence of a variety of microenviron-
ental factors. However, CD40L + IL-4 stimulation in combination
ith stromal cells may  partially protect from death induced by
I3K inhibition. This ﬁnding can be extended to IL-6 stimulation
s well but only for CLL cells expressing higher level of ZAP-
0.
.4. Inﬂammatory cytokine-induced increases in CLL cell
dhesion to stromal cells are correlated with ZAP-70 expression
nd blocked by PI3K inhibitor
We  examined the impact of inﬂammatory and T cell asso-
iated stimuli on interactions between CLL and stromal cells in
o-culture. CD40L + IL-4 stimulation resulted in ∼2-fold increase in
LL cell adhesion in both ZAP-70 positive and negative patients
Fig. 4A). Interestingly, IL-6 stimulation resulted in signiﬁcantly
ncreased stromal cell adhesion only among ZAP-70 positive
atients (Fig. 4A). IL-8-induced responses were highly variable,
ith a subset of patients showing large increases in adhesion
up to 4.5-fold) and others showing no enhancement. Notably,
L-6 and CD40L + IL-4 (but not IL-8)-induced adhesion was cor-
elated with ZAP-70 expression (Fig. 4B). For both groups of
atients, PI-103 treatment signiﬁcantly inhibited cytokine-induced
dhesion (signiﬁcance †  not shown in Fig. 4) and no signiﬁ-
ant difference was observed between patient groups. However,
ithin the ZAP-70 positive group, CD40L-IL-4 stimulation ren-
ered cells partially resistant to PI-103 inhibition of adhesion
Fig. 4A). These results suggest that inﬂammatory stimuli may
ifferentially impact stromal cell adhesion capability of ZAP-70
ositive and negative CLL cells, but the PI3K pathway is universally
equired.signiﬁcance (*p < 0.05) between cytokines and PBS stimulations was analyzed by
Friedman test with Dunn’s multiple comparison post test.
4. Discussion
Interaction of CLL cells with stromal cells within lymphoid
tissues can provide protective niches where leukemic cells receive
survival signals and are thus difﬁcult to eradicate through conven-
tional therapies [28,29]. Interventions that disrupt CLL cell–stromal
cell interactions are an attractive therapeutic concept and several
such interventions are under study, including blocking individual
chemokines and adhesion molecules involved in this process
[28,30]. The intracellular signaling processes driving CLL adhesion
to stromal cells are poorly understood, but will likely present
additional targets for therapy. Here we  evaluate the signiﬁcance of
the PI3K lipid kinases in CLL stromal cell adhesion and survival in
S.T. Lafarge et al. / Leukemia Research 38 (2014) 109– 115 113
Fig. 4. PI3K inhibition impairs cytokine-induced adhesion to S17 stromal cells. CLL-stromal cell co-cultures were stimulated with IL-6, IL-8, CD40L + IL-4 (all at 50 ng/mL)
or  PBS control. Percent adhesion after one day was  assessed as previously. (A) In some conditions, DMSO or PI-103 was  added to the co-culture system. To normalize,
the  reference used for each sample was the percent adhesion with PBS control treatment. Results shown represent median normalized numbers. Error bars represent the
interquartile range. Statistical signiﬁcance (†p < 0.05) between DMSO and PI-103 treatments was  analyzed by Wilcoxon paired test. Since these statistics reﬂect signiﬁcant
differences for all conditions, they are not shown in the ﬁgure. Statistical signiﬁcance (*p  < 0.05) between cytokines and PBS stimulations was  analyzed by Friedman test
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ultiple comparison post test. Statistics reported were calculated with absolute pe
L-6,  IL-8 or CD40L + IL-4 treatment. Correlation signiﬁcance was  analyzed by Spear
o-culture. PI3Ks represent attractive drug targets and are currently
he subject of numerous clinical trials for various cancers including
eukemia and lymphomas [17,18,23]. Since ZAP-70 is expressed
n a subset of CLL cells, we used ZAP-70 to categorize patients
roups and examined its potential signiﬁcance as a factor affecting
esponse to PI3K inhibitor treatment. To take into account the
resence of additional factors present in lymphoid tissue microen-
ironments of some patients, we have further investigated the
nterplay of stromal cells, IL-6, IL-8 and CD40L + IL-4, and the
otential signiﬁcance of these factors for PI3K inhibitor treatment.-70 positive and negative groups was  analyzed by Kruskal–Wallis test with Dunn’s
ages. (B) Correlation between ZAP-70 expression and percentage of adhesion after
est. Results from all panels are from 23 patients.
We  found substantial evidence that PI3Ks inﬂuence CLL–stromal
cell interaction and our results support the potential of PI3K
inhibitor therapy to act at the level of the leukemia microenviron-
ment to disrupt supportive niches, even in the presence of factors
that promote CLL adhesion such as pro-inﬂammatory cytokines.
Our results are consistent with recently published work show-
ing that PI3K inhibitors can disrupt CLL adhesion and survival
in stromal cell co-culture [13,17,18]. We  further compared the
response of ZAP-70 positive and negative patients and demon-
strate that PI3K inhibition may  be particularly effective in blocking
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tromal cell adhesion capabilities of ZAP-70 positive CLL cells.
his is important, as we and others ﬁnd that the CLL cells
rom this patient group frequently display enhanced adhesion
apacity and may  have distinctive interactions with the tissue
icroenvironment [31].
Furthermore, it is likely that cytokines and other immunological
ignals inﬂuence interaction of CLL with stromal cells within patient
ymphoid tissues. Since a signiﬁcant number of CLL patients show
levated levels of inﬂammatory mediators such as IL-6 and IL-8
9–11], we tested whether the presence of these stimuli inﬂuence
tromal cell adhesion. We  have recently found that levels of IL-6
nd IL-8 correlate with poor prognosis, and that these cytokines can
nhance CLL binding to stromal cells in vitro [27]. Here we ﬁnd that
nly the ZAP-70 positive group showed signiﬁcant enhancement
n adhesion capacity in the presence of IL-6. Given that IL-6 signals
ia the STAT3 pathway [32], it is attractive to imagine that ZAP-
0 could amplify STAT3 signaling, resulting in more CLL adhesion
o the supportive microenvironment. Importantly, PI3K inhibition
as able to inhibit CLL binding to stromal cells and CLL survival in
he presence of the inﬂammatory cytokines tested.
Our experiments showed that T cell-associated stimuli
D40L + IL-4 had a distinct effect on CLL cell survival and adhe-
ion to stromal cells. Notably, CD40L + IL-4 induced increases
n stromal cell binding and survival that were only partially
educed by PI3K inhibition. This suggests that CD40L + IL-4 may
nhance CLL stromal cell binding and survival capacity through
I3K-independent mechanisms. This conclusion is consistent with
ndings that most CD40L-induced responses in murine B cells,
uch as proliferation and isotype switching, are not blocked by
I3K inhibitors or genetic deﬁciency in PI3K [33,34]. In con-
rast, most murine B cell responses to IL-4 were shown to
epend highly on PI3K [35]. Thus, combined targeting of PI3K
nd CD40 might be necessary to thoroughly disrupt the inter-
ction of CLL cells within their supportive niches in lymphoid
issues. It would be of interest to determine whether combining
 PI3K inhibitor such as CAL-101/GS-1101 with an inhibitor tar-
eting the CD40/CD40L system such as dacetuzumab (SGN-40, a
umanized anti-CD40 monoclonal antibody) [17,36] is more effec-
ive for ZAP-70 positive CLL patients. This will be part of future
nvestigations.
Stromal cells can promote CLL survival via both cell contact-
ependant and soluble factors. It seems likely that the effect of
I-103 on CLL survival is at least partly due to disruption of cell
dhesion and thus disruption of contact-dependent survival sig-
als. In addition to impacting CLL cell signaling, PI3K inhibition
ay  also affect stromal cell biology by modulating the expression
f cell surface or secreted molecules. However, under the condi-
ions of our experiments we did not observe signiﬁcant effects of
I-103 on stromal cell survival, adhesion or morphology (data not
hown). Moreover, a few CLL patients were identiﬁed (12.5%) who
ere apparently completely resistant to the inhibitory effects of
I-103 on adhesion or cell survival in co-culture, suggesting the
tromal cells remain relatively intact and functional in the pres-
nce of the drug. Interestingly, these PI-103 resistant patients often
how discordant ZAP-70 and IgVH mutation status and may  deﬁne
 subgroup of CLL patients who are less dependent on the PI3K
athway. It is possible that speciﬁc genetic abnormalities may  be
ssociated with PI3K inhibitor resistance and it will be interesting
o examine the cytogenetic status of these patients. Thus while our
esults suggest that these drugs may  provide therapeutic beneﬁt in
oth ZAP-70 positive and negative CLL cells by disrupting protec-
ive niches; they also provide clinical and biomarker data regarding small subset of patients whose CLL cells may  be less dependent
n this pathway.
In summary, our study identiﬁes heterogeneity in CLL cell bind-
ng to stromal cells that correlates with ZAP-70 expression and canearch 38 (2014) 109– 115
be inﬂuenced by the inﬂammatory milieu. PI3K inhibition appears
to be a relatively robust strategy to disrupt CLL cell-stromal cell
interaction regardless of ZAP-70 status or presence of inﬂammatory
cytokines, with the possible exception that increased CLL adhe-
sion and survival induced by CD40L may  be less sensitive to PI3K
inhibitors. Our results indicate that treatment of CLL patients with
PI3K inhibitors may  be effective in disrupting protective interac-
tions with lymphoid tissue microenvironments and sensitizing to
other therapeutics.
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